Dabur India gets green light for Sesa Care amalgamation from BSE, NSE

Dabur India Limited announced on December 5, 2025, the receipt of an "observation letter with 'no adverse observations'" from BSE Limited and a "no objection" letter from the National Stock Exchange of India Limited (NSE) for the scheme of amalgamation of Sesa Care Private Limited with and into Dabur India Limited. These approvals relate to the scheme governing the amalgamation under Sections 230 to 232 of the Companies Act, 2013.

Both BSE and NSE confirmed that based on the submitted draft scheme and other documents, they have no adverse observations or objections to enable Dabur India to file the draft scheme with the National Company Law Tribunal (NCLT). The validity of these letters is six months from December 4, 2025 (BSE) and December 5, 2025 (NSE), within which the scheme must be submitted to the NCLT.

The observation letters include several requirements for additional disclosures to shareholders, such as details of assets, liabilities, net worth, and revenue, impact on revenue-generating capacity, rationale and synergies of the scheme, revised shareholding patterns, and pending actions against entities involved. The scheme remains subject to other statutory and regulatory approvals and consent from respective shareholders and creditors.